866 related articles for article (PubMed ID: 25514100)
1. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
2. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
3. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
Alpañés M; Luque-Ramírez M; Martínez-García MÁ; Fernández-Durán E; Álvarez-Blasco F; Escobar-Morreale HF
Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
[TBL] [Abstract][Full Text] [Related]
4. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
5. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
6. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
Ardawi MS; Rouzi AA
Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
[TBL] [Abstract][Full Text] [Related]
7. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
9. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
10. DHEA, DHEAS and PCOS.
Goodarzi MO; Carmina E; Azziz R
J Steroid Biochem Mol Biol; 2015 Jan; 145():213-25. PubMed ID: 25008465
[TBL] [Abstract][Full Text] [Related]
11. Ovarian hyperandrogenism in adolescents and young women with type I diabetes is primarily related to birth weight and body mass index.
Bizzarri C; Benevento D; Ravà L; Patera IP; Schiaffini R; Ciampalini P; Giannone G; Cappa M
Fertil Steril; 2011 Dec; 96(6):1497-1502.e1. PubMed ID: 21982726
[TBL] [Abstract][Full Text] [Related]
12. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
13. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
Yildiz BO; Yarali H; Oguz H; Bayraktar M
J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
[TBL] [Abstract][Full Text] [Related]
14. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
[TBL] [Abstract][Full Text] [Related]
15. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
Patlolla S; Vaikkakara S; Sachan A; Venkatanarasu A; Bachimanchi B; Bitla A; Settipalli S; Pathiputturu S; Sugali RN; Chiri S
Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
[TBL] [Abstract][Full Text] [Related]
16. [Insulin resistance and serum concentrations of ovarian and adrenal androgen in obese women without additional disease and with policystic ovary syndrome].
Olszanecka-Glinianowicz M; Banaś M; Zahorska-Markiewicz B; Kuglin D; Mokrzycka J; Mentel A
Endokrynol Pol; 2005; 56(6):921-6. PubMed ID: 16821212
[TBL] [Abstract][Full Text] [Related]
17. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
18. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.
Castelo-Branco C; Steinvarcel F; Osorio A; Ros C; Balasch J
Gynecol Endocrinol; 2010 Oct; 26(10):736-42. PubMed ID: 20569105
[TBL] [Abstract][Full Text] [Related]
19. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
Panidis D; Rousso D; Koliakos G; Kourtis A; Katsikis I; Farmakiotis D; Votsi E; Diamanti-Kandarakis E
Fertil Steril; 2006 Jun; 85(6):1778-83. PubMed ID: 16650418
[TBL] [Abstract][Full Text] [Related]
20. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.
Puurunen J; Piltonen T; Jaakkola P; Ruokonen A; Morin-Papunen L; Tapanainen JS
J Clin Endocrinol Metab; 2009 Jun; 94(6):1973-8. PubMed ID: 19318449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]